RxDoctor Payments Data

Aristotelis Vlahos, MD

Cardiovascular Disease · Tinton Falls, NJNPI 1184694028

Payments from drug & device makers

$15,897in general payments, 2019–2025

Across 966 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • Abbott$2K
  • AstraZeneca$2K
  • Amgen$1K
  • Medtronic$1K
  • Johnson & Johnson$869
  • plus $6K from 41 others

What the payments were for

  • Food & beverage$15,897100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,897 in reported general payments places this provider in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$1,086,900
Medicare patients
1,919
Services billed
7,373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban294$362,669
EliquisApixaban305$349,869
EntrestoSacubitril/Valsartan200$246,454
BrilintaTicagrelor128$111,842
FarxigaDapagliflozin Propanediol90$85,259
JardianceEmpagliflozin69$80,933
Repatha SureclickEvolocumab51$52,446
Praluent PenAlirocumab28$22,703
Repatha PushtronexEvolocumab21$20,407
Carvedilol ErCarvedilol Phosphate16$11,569
Atorvastatin Calcium917$10,534
Metoprolol Succinate562$9,258
NexlizetBempedoic Acid/Ezetimibe13$8,758
PradaxaDabigatran Etexilate Mesylate15$5,479
Icosapent Ethyl15$4,297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$869$362,669294 claims
PfizerEliquis$247$349,869305 claims
NovartisEntresto$3,103$246,454200 claims
AstraZenecaBrilinta, Farxiga$1,954$197,100218 claims
Boehringer IngelheimJardiance, Pradaxa$665$86,41184 claims
Esperion Therapeutics, Inc.Nexlizet$203$8,75813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Tinton Falls

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →